Arcus Biosciences, Inc. operates as a biotechnology company. The Company discovers, develops, and commercializes immunotherapies for the treatment of cancer patients. Arcus Biosciences serves customers in the United States.

Current Report (Form 8-K | Period ending 2024-06-06)

Current Report (Form 8-K | Period ending 2024-06-02)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arcus Biosciences Inc (RCUS US)

Current Report (Form 8-K | Period ending 2024-06-06)

Current Report (Form 8-K | Period ending 2024-06-02)

Current Report (Form 8-K | Period ending 2024-05-23)

Quarterly Report (Form 10-Q | Period ending 2024-03-31)

Current Report (Form 8-K | Period ending 2024-05-08)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)